DDAVP MELT TABLET (ORALLY DISINTEGRATING)
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
31-12-2015
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
DESMOPRESSIN (DESMOPRESSIN ACETATE)
Tillgänglig från:
FERRING INC
ATC-kod:
H01BA02
INN (International namn):
DESMOPRESSIN
Dos:
120MCG
Läkemedelsform:
TABLET (ORALLY DISINTEGRATING)
Sammansättning:
DESMOPRESSIN (DESMOPRESSIN ACETATE) 120MCG
Administreringssätt:
SUBLINGUAL
Enheter i paketet:
30
Receptbelagda typ:
Prescription
Terapiområde:
PITUITARY
Produktsammanfattning:
Active ingredient group (AIG) number: 0151664001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2006-09-08
Produktens egenskaper
_DDAVP® MELT (60μg, 120μg, 240μg) _
_Template Date: January 2010 _
_Page 1 of 34 _
_ _
PRODUCT MONOGRAPH
PR
DDAVP
®
MELT
Desmopressin acetate
60 μg, 120 μg and 240 μg
Oral Disintegrating Tablets
Antidiuretic
Ferring Inc.
200 Yorkland Boulevard
Suite 500
North York, Ontario
M2J 5C1
Date of Revision: DECEMBER 17, 2015.
SUBMISSION CONTROL NO: 187742
_DDAVP® MELT (60μg, 120μg, 240μg) _
_Template Date: January 2010 _
_Page 2 of 34 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
................................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
...................................
Läs hela dokumentet
